This thesis was divided in two parts. Part I demonstrated benefit of zoledronic acid addition to chemotherapy in terms of pathological response in postmenopausal women. Part II is all about... Show moreThis thesis was divided in two parts. Part I demonstrated benefit of zoledronic acid addition to chemotherapy in terms of pathological response in postmenopausal women. Part II is all about neoadjuvant endocrine therapy, and discusses the optimal duration of this treatment and the information on treatment efficacy that aromatase-inhibitor specific adverse events may provide. Show less
Dekker, T.J.A.; Charehbili, A.; Smit, V.T.H.B.M.; Dijke, P. ten; Kranenbarg, E.M.K.; Velde, C.J.H. van de; ... ; Kroep, J.R. 2015